

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/519,594 December 28, 2004 Filing Date INFORMATION DISCLOSURE **First Named Inventor** David Cavalla STATEMENT BY APPLICANT **Group Art Unit** Not yet assigned (use as many sheets as necessary) **Examiner Name** Not yet assigned Attorney Docket Number Sheet of **GJE-6758** 

•			· ·	U.S. PATENT DOCUMEN	TS	
Examiner Initials*	Cite No. 1	U.S. Patent Document  Number Kind Code <sup>2</sup> (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
LS	U1	6,284,770		Mangel et al.	09-04-2001	
LS	U2	4,695,568		Ninomiya et al.	09-22-1987	
	U3					
	U4					

			FOR	EIGN I	PATENT DOCMENT	rs		
Examiner Initials*	Cite No. 1	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	Т
		Office <sup>3</sup> Numt		Code <sup>5</sup> own)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Tو
					Merck Patent			
LS	F1	CA 2431	074	j	GMBH	06-27-2002	J	
LS	F2	DE 100 63	3 223		GMBH	06-20-2002	Abstract	
	F3							
	F4							
	F5							
	F7							
	F8							

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS						
Examiner Cite No. 1		Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
LS	R1	CROWELL M. D., "The Role of Serotonin in the Pathophysiology of Irritable Bowel Syndrome," <i>American Journal of Managed Care</i> , 2001, 7:S252-S260.				
LS	R2	EGUCHI J. et al., "The Anxiolytic-like Effect of MCI-225, a Selective NA Reuptake Inhibitor With 5-HT3 Receptor Antagonism," <i>Pharmacology, Biochemistry and Behavior</i> , 2000, 68:677-683.				
	R3					

Examiner	/Layla Soroush/	Date	07/17/2006
Signature	/ Lay La Boloubil/	Considered	07/17/2000

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.